Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

DARK SECRETS: Cara therapeutics s return on capital employed overview | Rare Historical Photos

According to data from Benzinga Pro, during Q1, Cara Therapeutics's (NASDAQ:CARA) reported sales totaled $4.79 million. Despite a 16.87% increase in earnings, the company posted a loss of $27.75 million. In Q4, Cara Therapeutics brought in $821.00 thousand in sales but lost $33.38 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.